Journals / Van Tıp Dergisi / 2017 / Cilt: 24 - Sayı: 4

Malignant Pleural Effusions: Diagnosis and Treatment

Malign Plevral Efüzyonlar: Tanı ve Tedavi

Pages
397–403
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In order to reduce intrapleural fluid volume, control associated symptoms, and improve quality of life and survival, it is imperative to identify the etiology of effusion and to individualize patient management.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Malignant pleural effusions are characterized by malignant cells in pleural fluid and appear in the course of various cancers.
📊
Key Findings & Data:MPE (Malignant Pleural Effusion) develops during the course of approximately 75% of cases with lung, breast, ovarian cancer, and lymphoma.
💡
Conclusion & Impact:In order to reduce intrapleural fluid volume, control associated symptoms, and improve quality of life and survival, it is imperative to identify the etiology of effusion and to individualize patient management.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Malignant pleural effusions are characterized by malignant cells in pleural fluid and appear in the course of various cancers. MPE (Malignant Pleural Effusion) develops during the course of approximately 75% of cases with lung, breast, ovarian cancer, and lymphoma. Its presence indicates that the underlying disease is advanced or widespread. In MPE the average survival is 3-12 months and varies by the cellular type of the underlying malignancy. Among various malignancies, ovarian cancer is associated with the longest survival and lung cancer with the shortest. The most widely accepted mechanism for the mechanism of development of MPE is increased pleural permeability and impaired drainage caused by metastatic disease. In addition to radiological examinations, cytological examination of pleural fluid and closed or open pleura biopsies are the diagnostic tools used for MPE. Treatment is aimed at controlling symptoms and increasing quality of life rather than treating the primary disease. In order to reduce intrapleural fluid volume, control associated symptoms, and improve quality of life and survival, it is imperative to identify the etiology of effusion and to individualize patient management.

Özet

Plevral sıvıda malign hücre görülmesi ile karekterize olan malign plevral efüzyonlar farklı tiplerdeki kanserlerin seyri sırasında görülmektedir. Akciğer kanserli, lenfomalı, meme ve over maligniteli olguların yaklaşık %75'inde hastalığın seyri sırasında MPE gelişir. Mevcudiyeti hastalığın yaygın ya da ilerlemiş olduğunun ve yaşam beklentisinin azaldığının bir göstergesidir. MPE'da hayatta kalım süresi ortalama 3-12 aydır. Bu süre hastada mevcut malignitenin hücre tipine ve evresine göre değişir. MPE gelişen malignite olgularından en uzun yaşam süresi over kanserlerinde tespit edilirken, en kısa akciğer kanserlerinde görülür. Gelişiminde en fazla kabul gören mekanizma, metastatik hastalığın plevrada yol açtığı permeabilite artışı ve bozulmuş drenajdır. Radyolojik değerlendirmenin ardından, sıvının sitolojik incelemesi ve kapalı ya da açık plevra biopsileri uygulanan tanısal girişimlerdir. Tedavi birincil hastalığı tedavi etmek yerine semptomları kontrol altına alıp yaşam kalitesini arttırmaya yöneliktir. İntraplevral sıvı hacmini azaltılması, ilişkili semptomların kontrol altına alınması ve yaşam kalitesini ve sağ kalımı iyileştirmek için efüzyonun etiyolojisinin ortaya konularak, hasta tedavisinin özelleştirilmesi gerekir.

🔖

Cite This Article

ÇOBANOĞLU, U., KIZILTAN, R., KEMİK, Ö. (2017). Malignant Pleural Effusions: Diagnosis and Treatment. Van Tıp Dergisi, Cilt: 24 - Sayı: 4, 397–403. https://ajindex.com/articles/334528

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Chernow B, Sahn SA. Carcinonomatous involvement of the pleura: an analysis of 96 patients. Am J Med 1977; 63(5): 695-702
  2. Sahn SA. Malignant pleural effusions. Semin Respir Crit Care Med 2001; 22(6): 607-616
  3. Johnston WW. The malignant pleural effusion: a review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer 1985; 56(4): 905-909
  4. Postmus PE, Brambilla E, Chansky K, Crowley J, Goldstraw P, Patz EF Jr et al. The IASLC Lung Vancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007; 2(8): 686-693
  5. Kolschmann S, Ballin A, Gillissen A. Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest 2005; 128(3): 1431-1435
  6. Porcel JM. Pleural fluid biomarkers: beyond the Light criteria. Clin Chest Med 2013; 34(1): 27-37
  7. Koşar F. Malign Plevral Efüzyona Yaklaşım. Güncel Göğüs Hastalıkları Serisi 2013; 1(3): 108- 114
  8. Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax 2010; 65(2): 32-40
  9. Salyer WR, Eggleston JC, Erozan YS. Efficacy of pleural needle biopsy and pleural fluid cytopathology in the diagnosis of malignant neoplasm involving the pleura. Chest 1975; 67(5): 536-539
  10. Sears D, Hajdu SI. The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions. Acta Cytol 1987; 31(2): 85-97
  11. Hsu C. Cytologic detection of malignancy in pleural effusion:a review of 5,255 samples from 3,811 patients. Diagn Cytopathol 1987; 3(1): 8-12
  12. Zarogoulidis K, Zarogoulidis P, Darwiche K, Tsakiridis K, Machairiotis N, Kougioumtzi I et al. Malignant pleural effusion and algorithm management. J Thorac Dis 2013; 5(4): 413-419
  13. Benlloch S, Galbis-Caravajal JM, Martín C, Sanchez-Paya J, Rodríguez-Paniagua JM, Romero S et al. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion. Cancer 2006; 107 (8): 1859-1865
  14. Edmondstone WM. Investigation of pleural effusion: comparison between fibreoptic thoracoscopy, needle biopsy and cytology. Respir Med 1990; 84 (1): 23-26
  15. Lee YC, Light RW. Management of malignant pleural effusions. Respirology 2004; 9(2): 148- 156
  16. Hung MS, Lin CK, Leu SW, Wu MY, Tsai YH, Yang CT. Epidermal growth factor receptor mutations in cells fr